Posted by Michael Wonder on 09 Sep 2025
Reimbursement delay leaves Korean patients waiting for Padcev-Keytruda first-line therapy
8 September 2025 - The first-line combination therapy of Padcev and Keytruda for metastatic urothelial carcinoma was not even submitted to the Cancer Disease Review Committee (CDRC).
Last Wednesday, the HIRA convened a CDRC meeting, but the Padcev first-line combination therapy was not included in the agenda.
